{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:20:49Z","timestamp":1777576849310,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R011AI117734"],"award-info":[{"award-number":["R011AI117734"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI125841"],"award-info":[{"award-number":["R01AI125841"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.05.034","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T04:15:15Z","timestamp":1496117715000},"page":"6803-6806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"PA","title":["Human immune responses against Shigella and enterotoxigenic E. coli : Current advances and the path forward"],"prefix":"10.1016","volume":"35","author":[{"given":"Monica A.","family":"McArthur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Milton","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.034_b0005","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.034_b0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/JCM.27.1.162-167.1989","article-title":"Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections","volume":"27","author":"Cohen","year":"1989","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.05.034_b0020","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.034_b0025","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1128\/IAI.60.6.2218-2224.1992","article-title":"Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen","volume":"60","author":"Kotloff","year":"1992","journal-title":"Infect Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clim.2013.03.009","article-title":"Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a","volume":"148","author":"Wahid","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/427662","article-title":"Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea","volume":"191","author":"Rao","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.034_b0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","article-title":"Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala","volume":"14","author":"Behrens","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.034_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/CVI.00148-16","article-title":"Monoclonal antibodies to shigella lipopolysaccharide are useful for vaccine production","volume":"23","author":"Lin","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0055","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0060","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.vaccine.2008.12.021","article-title":"Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a phase 2, randomized, double-blind placebo-controlled trial","volume":"27","author":"Launay","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.034_b0065","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.4049\/jimmunol.0900978","article-title":"Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity","volume":"184","author":"Sellge","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/CVI.00617-15","article-title":"Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407","volume":"23","author":"Chakraborty","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0075","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/CDLI.8.3.482-488.2001","article-title":"Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes","volume":"8","author":"Chang","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0080","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/CVI.05342-11","volume":"18","author":"Harro","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0085","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/CVI.00364-12","article-title":"The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease","volume":"19","author":"Darsley","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.034_b0090","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/S0264-410X(00)00056-6","article-title":"Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children","volume":"18","author":"Qadri","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.034_b0095","doi-asserted-by":"crossref","first-page":"e0005291","DOI":"10.1371\/journal.pntd.0005291","article-title":"Impact of CD4+ T cell responses on clinical outcome following oral administration of wild-type enterotoxigenic Escherichia coli in Humans","volume":"11","author":"McArthur","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.05.034_b0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.05.034_b0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ajcn.81.2.495","article-title":"Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis","volume":"81","author":"Rahman","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.vaccine.2017.05.034_b0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3329\/jhpn.v29i5.8896","article-title":"Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I","volume":"29","author":"Sayem","year":"2011","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2017.05.034_b0115","doi-asserted-by":"crossref","first-page":"e0172163","DOI":"10.1371\/journal.pone.0172163","article-title":"Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout","volume":"12","author":"Necchi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.05.034_b0120","first-page":"257","article-title":"Whole gut lavage fluid analysis: a minimally invasive method for study of mucosal immunity and inflammation","volume":"41","author":"Ghosh","year":"2000","journal-title":"Methods Mol Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T21:49:22Z","timestamp":1602193762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17306588"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}